Innate Pharma (IPHA) to Release Earnings on Wednesday

Innate Pharma (NASDAQ:IPHA - Get Free Report) is scheduled to announce its earnings results before the market opens on Wednesday, November 13th.

Innate Pharma Price Performance

Innate Pharma stock traded down $0.00 during mid-day trading on Friday, reaching $1.84. 7,075 shares of the company were exchanged, compared to its average volume of 9,069. The company has a fifty day simple moving average of $2.09 and a 200-day simple moving average of $2.26. Innate Pharma has a 12 month low of $1.57 and a 12 month high of $3.15.

Analysts Set New Price Targets

A number of equities analysts have commented on IPHA shares. HC Wainwright restated a "buy" rating and set a $11.50 price objective on shares of Innate Pharma in a research note on Friday, September 13th. Evercore ISI raised Innate Pharma to a "strong-buy" rating in a report on Monday, September 16th.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.